Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Parkinson’s Gene Therapy Wires New Brain Circuits

Parkinson’s Gene Therapy Wires New Brain Circuits

WEDNESDAY, Nov. 28, 2018 — An experimental gene therapy for Parkinson’s disease seems to work by rewiring key areas of the brain, a new study finds.

The researchers focused on 15 Parkinson’s patients who, in an earlier trial, had received so-called GAD gene therapy. GAD is an enzyme that spurs the production of a brain chemical involved in movement control.

In the previous trial, patients had shown improvements in their movement problems after receiving infusions of the GAD gene into the brain.

What hadn’t been clear was precisely why, said researcher Dr. David Eidelberg, who directs the Center for Neurosciences at the Feinstein Institute for Medical Research, in Manhasset, N.Y.

So for the new study, Eidelberg’s team examined specialized brain scans from 15 of the trial patients. The investigators found an unexpected answer: The gene therapy did not change the abnormal brain circuitry that marks Parkinson’s disease.

Instead, it essentially rewired a small area of the brain, to partially compensate for the faulty circuitry.

“It created its own set of circuits,” Eidelberg explained. “The disease circuitry continues — so this is not a cure.”

Still, he said, the gene therapy seems to spur new brain connections that can benefit people with Parkinson’s.

The study findings were published online Nov. 28 in Science Translational Medicine.

Parkinson’s disease affects nearly 1 million people in the United States alone, according to the Parkinson’s Foundation.

The root cause is unclear, but as the disease progresses, the brain loses cells that produce dopamine — a chemical that regulates movement. As a result, people suffer symptoms like tremors, stiff limbs, and balance and coordination problems that gradually worsen over time.

There are treatments to lessen those symptoms, including medications that boost dopamine levels or mimic the actions of dopamine. Another option for some patients is deep brain stimulation (DBS), where electrodes are implanted in a specific brain area to deliver continuous electrical pulses. It’s thought to help by suppressing abnormal electrical activity.

GAD gene therapy is done by inserting the gene into an inactivated cold virus. That viral “vector” is infused into a specific brain area called the subthalamic nucleus — which is one of the brain regions targeted in DBS treatment.

Originally, Eidelberg added, researchers thought the gene therapy would work in a “DBS-like” way.

But based on the new findings, that’s not the case.

Dr. Michael Okun is medical director of the Parkinson’s Foundation. He called the study “fascinating.”

“It showed that GAD gene therapy, unlike subthalamic nucleus DBS, did not change the expected Parkinson’s disease brain network,” Okun said. “Instead, it co-opted adjacent non-motor pathways.”

Why does that matter? One reason, according to Okun, is that it offers an “important lesson” for the gene therapy field going forward.

Researchers cannot make assumptions about a therapy’s “mechanism of action,” he said, based on the brain area it targets.

Eidelberg made another point: In future studies, researchers could use brain imaging to be sure that patients’ symptom improvements are due to a true effect of the gene therapy — rather than a “placebo effect.”

In the original trial, which involved a few dozen Parkinson’s patients, some were randomly assigned to receive GAD gene infusions. The rest underwent a “sham” procedure for comparison.

Over six months, both groups showed improvements in movement symptoms like stiffness and tremor. But the gene therapy group saw greater gains.

“It wasn’t a slam dunk,” Eidelberg stressed. “But they were doing better. And that persisted to the one-year mark.”

With any such therapy, there is a theoretical concern that the infused gene will have unintended effects.

“What we’ve seen is that this gene stays put,” Eidelberg said. “It doesn’t percolate all over the brain.”

In the original trial, there were no red flags, according to the researchers. The most common side effects were temporary headaches and nausea.

Various research teams are looking at different approaches to gene therapy for Parkinson’s. The hope, Eidelberg said, is to develop additional options that work for at least some patients — possibly freeing them from taking daily medications.

At this point, he noted, there is “a lot of interest” in doing a larger, later-stage trial of the GAD therapy. But none has begun yet.

The current study was funded by Neurologix Inc., the company that developed the gene therapy.

More information

The Parkinson’s Foundation has more on Parkinson’s treatment.

© 2018 HealthDay. All rights reserved.

Posted: November 2018

Tagged with:

About author

Related Articles